Clinical Trial

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Name: Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases — clinical trial record (NCT07558850)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases. 36-72 patients are planned to be enrolled in the dose-escalation trial.

Trial Details

NCT Number	NCT07558850
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Rui Therapeutics Co., Ltd
Conditions	Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis
Enrollment	72 participants
Start Date	2026-05-10
Primary Completion	2028-01-10 (estimated)
Study Completion	2029-01-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-30